Individualización del tratamiento en Adenocarcinoma de pulmón tras la primera línea de quimioterapia
|
Individualización del tratamiento en Adenocarcinoma de pulmón tras la primera línea de quimioterapia |
1 |
|
Número de diapositiva 2 |
2 |
|
Retos |
3 |
|
Tratamiento estándar en 2L para CPNM avanzado hasta 2014 |
4 |
|
Estancamiento terapéutico de la SG en 2ª línea de CPNM durante 10 años |
5 |
|
Número de diapositiva 6 |
6 |
|
Número de diapositiva 7 |
7 |
|
Número de diapositiva 8 |
8 |
|
Número de diapositiva 9 |
9 |
|
List of contraindications for 2nd line therapy in Non-squamous Non-Small-Cell Lung Cancer |
10 |
|
Individualización del tratamiento |
11 |
|
Anti-PD1 and anti-PDL1 therapies in previously treated advanced NSCLC: trial design |
12 |
|
Efficacy summary for anti-PDL1 and anti-PD1 therapies in previously treated NSCLC |
13 |
|
Immunotherapy in previously treated patients: efficacy by PD-L1 status |
14 |
|
Tumor and Immune Biomarkers Being Evaluated to Predict Better Outcomes to Immuno-Oncology Therapy |
15 |
|
Número de diapositiva 16 |
16 |
|
Exclusion criteria for anti-PDL1 and anti-PD1 therapies in previously treated NSCLC regarding the use of antibiotics |
17 |
|
Fármacos anti-VEGF activos frente a Cáncer de Pulmón No Microcítico |
18 |
|
Nintedanib: inhibidor triple angioquinasa |
19 |
|
Número de diapositiva 20 |
20 |
|
Número de diapositiva 21 |
21 |
|
CheckMate 057: Updated 2-year survival rates show similar results as LUME-Lung 1 |
22 |
|
LUME LUNG 1: Significant Improvement in Disease Control Rate by Independent Central Review |
23 |
|
LUME LUNG 1: Best Change from Baseline in Tumour Size based on Central Independent Review |
24 |
|
Waterfall Plots CheckMate 057: ORR |
25 |
|
Número de diapositiva 26 |
26 |
|
Check Mate 057: Risk of early death (EPAR) |
27 |
|
OS by PD-L1 Expression |
28 |
|
Conclusions on clinical efficacy (EPAR) |
29 |
|
Conclusions on clinical efficacy (EPAR) |
30 |
|
Número de diapositiva 31 |
31 |
|
OAK: OS in the ITT population |
32 |
|
OAK: OS by PD-L1 subgroup |
33 |
|
OAK: OS by histology |
34 |
|
Lessons from the LUME Trials |
35 |
|
Número de diapositiva 36 |
36 |
|
Número de diapositiva 37 |
37 |
|
Patients with aggressive course of disease – Results from LUME Lung 1 and Checkmate 057 |
38 |
|
LUME-Lung 1: Tumour growth over time |
39 |
|
Early vs Late Progressors:Mechanistic Hypothesis |
40 |
|
Número de diapositiva 41 |
41 |
|
REVEL: Overall Survival – ITT Population |
42 |
|
REVEL: Forest Plot of OS by Subgroups – Unstratified Analysis |
43 |
|
Supervivencia libre de progresión |
45 |
|
SLP: Análisis Subgrupos |
46 |
|
Individualización del tratamiento |
47 |
|
Individualización: Principales factores para la toma de decisiones |
48 |
|
Retos |
49 |
|
1st line NSCLC: IO Positive Ph3 trials to date |
50 |
|
There are several ongoing phase III studies of anti-PDL1/PD1 therapy in first-line NSCLC |
51 |
|
Número de diapositiva 52 |
52 |
|
Pero, ¿qué sabemos de la eficacia de los tratamientos a la progresión de inmunoterapia? |
53 |
|
Efficacy to salvage chemotherapy following exposure to PD-1 or PD-L1 inhibitors |
54 |
|
Número de diapositiva 55 |
55 |
|
Efficacy to salvage chemotherapy following exposure to PD-1 or PD-L1 inhibitors |
56 |
|
Número de diapositiva 57 |
57 |
|
Número de diapositiva 58 |
58 |
|
Número de diapositiva 59 |
59 |
|
Conclusiones |
60 |
|
Número de diapositiva 61 |
61 |